Over 100 organoid
OcellO offers extracellular matrix-embedded
organoid cultures for testing of small molecules
and antibodies for oncology and immuno-oncology.
Precise detection of therapeutic responses such as
activity, toxicity, synergy as
well as mode of action and interactions with
added immune cells are tested in 3D culture and
quantified using OcellO’s Ominer™ 3D image
Well-characterized patient derived colon organoids from normal and tumor material
The variation in mutations detected in colorectal cancer organoids derived from different patients results in diverse growth morphologies in response to the culture environment. Image-based analysis of organoids gives more insight into the effects of compounds on the complex tumor biology, revealing effects and activities that cannot be revealed by conventional measurements of cell viability.
Rich, quantitative data describing drug responses
OcellO’s advanced 3D image analysis measures tumour killing and non-lethal toxicities in both tumor and normal organoids derived from the same patient. This can help to predict potential off-target effects in subsequent in vivo studies. Here, 5-FU induces killing of tumor organoids, and thinning of the epithelial cell layer of normal colorectal organoids.
OcellO’s high content 3D screening platform enables basic measurement of number, shape & size of organoids, individual cells and nuclei. Additional intricate analysis of network formation, protrusions, lumen formation and planar polarity measurements are performed in order to obtain unique characterization of treatment effects on organoids with specific mutations and diverse genetic backgrounds.
- > 80 sequenced tumour and normal intestinal organoids
- Customizable high throughput screening platform (384-well plate format)
- Measurement of > 500 features such as number, shape & size of nuclei,
organoid & lumen formation or infiltration of immune cells
- Quantitative analysis of growth, morphology, proliferation, cell cycle arrest,
cell death, apoptosis and toxicity
- Functional testing of antibodies, ADC’s, immune cell interactions and
OcellO licenses tumor and normal colon organoids derived from biopsies from more than 100 patients by Hubrecht Organoid Technology (HUB). These genetically characterized organoids are expanded from their stem-cell compartment and cultured in 3D by OcellO and seeded in a 384-wells plate format for high throughput screening.
Assays can be customized to fit project needs – the organoid screening platform is suitable for testing libraries or dose ranges of immuno-oncology therapies, small molecules, (bispecific) antibodies, ADCs, compound combinations, inflammatory agents and toxic agents.
After a typical exposure time of 7 days the hundreds of organoids per well are fixed and stained to capture the cellular and tissue organisation of each individual organoid by automated z-stack imaging, followed by 3D image analysis in OcellO’s Ominer™ platform.
The >500 different morphological parameters that are measured are subsequently interrogated to obtain a drug response profile and determine the mode of action, growth (inhibiting) effect, promotion of cell death, alterations in polarity and reversal of mutation-driven signatures.